HAE Canada remains committed to keeping members informed about upcoming clinical research studies for HAE treatments. We are pleased to let HAE Canada members know there are two important studies that are currently seeking HAE patients to participate at Canadian research clinics.
One study will be evaluating an investigational drug to see how well it prevents HAE attacks in adult patients with Type 1 & 2 HAE, as well as those with HAE with Normal C1 Inhibitor. To be eligible for this year-long study, you must:
- Be 19-65 years of age,
- Have been diagnosed with HAE, and
- Have a history of HAE attacks.
The other study is to evaluate the safety of TAKHZYRO (Lanadelumab) in children between the ages of 2 and less than 12 years old. To be eligible, children must:
- have a diagnosis of HAE Type I or II,
- have a history of at least one HAE attack every three months,
- be between 2 and less than 12 years old.
All travel expenses associated with either of these studies will be fully paid for, as well as compensation for your time spent in visits.
Clinical Trials: Information for Patients and Caregivers
Understanding what clinical trials are can help you decide if a clinical trial might be an option for you, or maybe you have a friend or family member with HAE and are wondering if a clinical trial, is right for them.
This page provides some basic information about clinical trials, to help you understand what’s involved in taking part. This includes information about the benefits and risks; who is responsible; and how your safety is protected.
What are clinical trials?
Clinical trials are research studies that involve people. They are one step in the long process that begins with research in a lab. Most treatments today are the results of past clinical trials.
HAE clinical trials are designed to test new ways to treat HAE.
Every trial has a person in charge, usually a doctor, who is the principal investigator. The principal investigator prepares a plan for the trial, called a protocol. The protocol explains, what will be done during a trial. It also contains information that helps the doctor decide if this treatment is right for you. The protocol includes information about:
Why are Clinical Trials important?
Clinical trials are key to developing new treatment options for HAE. It is through clinical trials that researchers can determine wether new treatments are safe and effective and work better than current treatments.
When you take part in a clinical trial you add knowledge about HAE and help improve care.
Who is involved in Clinical trials?
Designing and running a clinical trial requires the skills of many different types of experts.
Each team may be set up differently at different sites. Typical team members and their responsibilities include:
Principal Investigator – supervises and is responsible for all aspects of a clinical trials. This person:
- develops the concept for the trial;
- writes the protocol;
- submits the protocol for Ethics Board review and approval;
- directs the recruitment of patients;
- manages the informed consent process;
- supervises data collection, analysis, interpretation and preparation; and
- is responsible for the safety and welfare of each subject.
Research Nurse – manages the collection of data throughout the course of the clinical trial. This person:
- educates staff, patients and referring health care providers about the trial;
- communicates regularly with the principal investigator; and
- assists the principal investigator with monitoring, quality assurance, audits and data management and analysis.
Data Manager – manages the collection of data throughout the course of the clinical trial. This person:
- enters the data;
- works with the principal investigator and research nurse to identify which data will be trailed;
- provides data monitoring agencies; and
- prepares summaries for interim and final data analysis.
Staff physician or Nurse – helps take care of patients during a clinical trial. This person:
- treats patients according to the clinical trial protocol;
- assesses and records how each patient responds to treatment and the side effects they may have;
- works with the principal investigator and research nurse to report trends of how patients are doing in the treatment; and
- manages each patient’s care.
Patient Safety in Clinical Trials
If you are thinking about taking part in a clinical trial, you may have questions such as:
- Are there risks to taking part in this trial?
- Who is watching out for any problems?
- Who is making sure that participants are safe?
- Is the trial trying to answer and important research question?
In fact, there are Health Canada rules in place to help ensure the safety and ethics of clinical trials. You will be protected through:
- the informed consent process;
- careful review and approval of clinical trials by Scientific Experts, Health Canada, and Ethics Review Board; and
- careful monitoring of the trial by Ethics Board.
Paying for Clinical Trials
As you think about taking part in a clinical trial, you will face the issue of how to cover costs. Research costs are those related to taking part in the trial. Often these costs are not covered by insurance and may be covered by the trials sponsor. Expenses include:
- the study drug;
- lab tests performed purely for research purposes;
- additional tests performed solely for the trial; and
- any incidental costs to you, the patient related to participating in the study, such as parking etc.
When you take part in a trial you may have extra doctor visits that you would not have with standard treatment. These extra visits can add costs for transportation and even child care.
Informed consent is a process through which you learn details about the trial before deciding whether to take part. This includes a critical part of ensuring patient safety in research.
During the informed consent process, the research team will explain the trials:
- risks and benefits; and
- chances of receiving the placebo vs study drug.
They will also explain your rights; including your right to:
- make a decision about participating; and
- leave the study at any time.
Before agreeing you have the right to:
- learn about all your treatment options;
- learn all that is involved in the trials, including all details about treatment, tests, and possible risks and benefits;
- discuss the trial with the principal investigator, other members of the research team, your family, and/or your physician; and
- both hear and read information in a language you can understand.
After discussing the study with you, the research team will give you an informed consent form to read. The form includes written details about information that was discussed with you and describes the privacy of your medical records. If you agree to take part in the study, you sign the form. But even after you sign the consent form, you can leave the study at any time. You can always ask questions and as new information becomes available, the research team will inform you.
Preparing for a Clinical Trial
- What is the purpose of the trial?
- Why do the researchers believe that the treatment being studied may be better than the one being used now? Why may it not be better?
- How long will I be in the trial?
- What kinds of tests and treatments are involved?
- How will I be informed about the trials results?
- How long do I have to make up my mind about joining the trial?
- Who can I speak with about questions I have during and after the trial?
- Who will be in charge of my care?
- Is there someone I can talk to who has been in the trial?
Past clinical trials
HAEC Clinical Trail 2018
HAE Canada is committed to keeping members informed about upcoming clinical research studies for HAE treatments. We are excited to let HAE Canada members know that Phase 3 prophylaxis trial for BCX7353 (APeX-2) has begun in the United States and is currently seeking Canadian participants.
The APeX-2 study is evaluating the safety and effectiveness of an investigational oral medication that may prevent hereditary angioedema (HAE) attacks. You can visit www.haeresearch.com to find important details regarding the research study.
Who is eligible?
If you (or your child) are interested in participating in this clinical research study evaluating an investigational alternative to injections or infusions to prevent HAE attacks, you might be eligible if you:
- Have been diagnosed with HAE Type 1 or 2
- Are 18 years old or older
- Or are the parent or legal guardian of a child 12-17 years old diagnosed with HAE who weighs at least 40 kg or 88 lbs
- Have HAE attacks
- Have access to and can provide your own HAE acute treatment during the study
If you are interested in participating in this important 48 week clinical research study, we ask that you contact your Regional Director listed below: